Add Row
Add Element
cropper
update
Pulse On Wellcare
update
Add Element
  • Home
  • Categories
    • Healthcare
    • Trends
    • Insights
    • Southwest
    • Strategies
    • Prevention
    • Lifestyle
    • Mental Health
    • Preventative Care
    • Nutrition & Meal Planning
    • Telemedicine Access
    • Workplace Wellness
    • Wellness Tips
  • Events
  • Healthy Aging
October 02.2025
2 Minutes Read

The Closure of Long COVID Clinics: What It Means for Patients

Clinic entrance showing closure, Long COVID Clinic Closures highlighted.

Long COVID Clinics Face Shutdowns: A Growing Concern

The closure of specialized Long COVID clinics, such as the recent shut down of the University of North Carolina (UNC) COVID Recovery Clinic, has sparked alarm among patients relying on these crucial services. As highlighted in a report by The Sick Times, thousands of Americans, including individuals like Gillian Lizars and Doreen Stein-Seroussi, found essential care at these clinics. With the loss of services like vestibular physical therapy and support for disability paperwork, many patients are left in a vulnerable state, facing uncertainty regarding their treatment and financial stability.

The Fragile Landscape of Long COVID Care

Data shows quick closures of Long COVID clinics across the U.S., Canada, and even the U.K., further exacerbating the plight of those wishing to seek necessary care. Unlike traditional healthcare practice, treatment for Long COVID requires specialized knowledge, indicating a pressing need for continued support for patients as they face the aftereffects of their illness. Reports from the U.K. emphasize that even as the need grows—with almost 2 million individuals in England and Scotland currently affected by Long COVID—the number of available services continues to decline.

Challenges in Treatment Access

Research indicates that, post-closure, patients may require alternate lines of care through primary physicians, who may lack the background or availability to provide adequate care for Long COVID symptoms. This transfer of responsibility places undue stress on patients who have already experienced significant challenges in managing their health. One such example is Lizars, whose confidence in her disability applications diminishes as she loses contact with providers familiar with her complex case.

The Call for Action: Advocating for Sustainable Care

Advocacy groups, like #MEAction in North Carolina, are calling for immediate action from the government to preserve and restore funding for these clinics. Patients and advocates argue that the continued support of specialized clinics is integral not only for individual recovery but for the stabilization of the healthcare system at large. As emphasized by advocates in the U.K., proper management of Long COVID not only aids patients but also promotes societal participation, thus bringing financial benefits as a result of improved autonomy.

The Future of Long COVID Care: Weighing Our Options

As these closures continue, it is essential for policymakers to develop comprehensive Long COVID strategies that ensure the condition receives the resources it requires for effective management and care. Acknowledging the unique complexities of Long COVID will be crucial in addressing ongoing patient needs. Investing in Long COVID clinics could ultimately provide opportunities not just for recovery but also for reintegration into everyday life, mitigating further healthcare strain.

Strategies

30 Views

0 Comments

Write A Comment

*
*
Please complete the captcha to submit your comment.
Related Posts All Posts
04.08.2026

Discovering the Facts: Hormonal Contraception and IIH Risk Explained

Update Understanding the Link Between Hormonal Contraception and IIHRecent discussions around hormonal contraception (HC) have raised concern regarding its potential link to idiopathic intracranial hypertension (IIH), a disorder that involves increased pressure in the skull without a clear cause. This condition, which primarily affects women and can lead to severe headaches and even vision loss, has prompted researchers to investigate the role of HC in its prevalence.Recent Research FindingsA significant meta-analysis published this month in Neurology consolidates data from 13 observational studies, analyzing over 5,351 women with IIH against a control group of 669,260 women without the condition. The authors, led by Dr. Arun N.E. Sundaram from the University of Toronto, concluded that there is no significant association between HC use and the prevalence of IIH.This finding provides some reassurance for those concerned about the implications of hormonal contraception. The studies evaluated various forms of HC, including birth control pills, intrauterine devices (IUDs), and injectable contraceptives like medroxyprogesterone acetate. Despite fears that these methods could elevate the risk of IIH, data showed no meaningful correlation.The Importance of Data DiversityWhile the findings are promising, it is essential to recognize their limitations. Some of the included studies had small participant sizes and varied quality, suggesting that larger, more diverse studies are necessary to obtain conclusive results. As Dr. Sundaram pointed out, "health advice for people living with IIH has been inconsistent due to concerns about hormonal contraception. Our analysis can help clarify these concerns for patients and practitioners alike."Exploring Other Contributing FactorsObesity remains a significant risk factor for IIH. The condition predominantly affects women during their reproductive years, making it crucial for healthcare providers to guide patients in recognizing symptoms and understanding their risk profile based on holistic factors, including lifestyle and body weight, rather than solely focusing on contraception methods.The Broader Implications for Women’s HealthAccess to reliable contraception remains an integral part of women’s healthcare. Misperceptions regarding HC and its effects on conditions like IIH can lead to unnecessary alarm and could potentially discourage women from using effective contraceptive methods. As healthcare professionals and medical research evolve, clear and evidence-based communication is essential to empower women to make informed choices about their reproductive health.Conclusion: What This Means For YouAs recent studies indicate a lack of association between hormonal contraception and IIH, it not only provides reassurance but also highlights the importance of making informed healthcare decisions. If you're navigating choices related to hormonal contraception, consider having an open discussion with your healthcare provider. This will help ensure that your decisions are based on comprehensive insights into both your reproductive health and any existing conditions.

04.07.2026

Gotistobart Emerges as Leading Chemotherapy-Free Therapy for NSCLC

Update Gotistobart: A Promising New Treatment for Squamous NSCLC Recent clinical trial results have illuminated the potential of gotistobart, a novel chemotherapy-free treatment for non-small cell lung cancer (NSCLC). In phase 3 of the PRESERVE-003 trial presented at the 2026 European Lung Cancer Congress (ELCC), gotistobart, an anti-CTLA-4 antibody seemed to outperform traditional chemotherapy with docetaxel for patients who had previously undergone multiple lines of treatment, including anti-PD-1 and PD-L1 therapies. Importance of Targeted Immunotherapy Gotistobart operates by selectively targeting regulatory T cells within the tumor microenvironment, enhancing the immune system's ability to combat cancer while minimizing peripheral damage. According to Kai He, MD, the lead study author, this mechanism signifies a shift towards more precise and effective oncology therapies, aligning with contemporary demands for personalized medicine in treating challenging cancer types. As many patients with squamous NSCLC often have limited treatment options after conventional therapies fail, gotistobart represents an invaluable alternative. Comparative Effectiveness and Survival Metrics The findings from this trial showed that participants receiving gotistobart experienced a median overall survival (OS) that had not yet been reached within the 14.5-month follow-up, while the OS for those treated with docetaxel was reported at 9.95 months. The objective response rate (ORR) for gotistobart was 20%, compared to just 4.8% for docetaxel. Moreover, the duration of response favored gotistobart, with a median of 11 months compared to 3.8 months for docetaxel. Safety and Tolerability of Gotistobart Safety evaluations indicated that gotistobart’s profile remains manageable and generally consistent with expectations derived from earlier trials. While 42.2% of patients experienced serious adverse events, these were balanced with docetaxel’s 48.3%. Common side effects included gastrointestinal issues and infusion-related reactions but notably did not present new unexpected toxicities. This safety alignment supports the case for gotistobart's viability as a treatment option for NSCLC patients. Seek Further Insights into Cancer Treatment Trends The implications of this study stretch beyond numbers; they signify a potential pivot in cancer treatment paradigms. For patients with pretreated squamous NSCLC, gotistobart offers a chance for better outcomes and emphasizes the need for continued innovation in immunotherapy. As cancer treatment evolves, understanding these advancements can greatly inform patient options and decisions. Stay informed about the latest developments in oncology and consider engaging with your healthcare provider to discuss innovative treatments that may be suitable for you or your loved ones.

04.05.2026

New Alopecia Areata Treatments: How JAK Inhibitors Offer Hope

Update Groundbreaking Advances in Alopecia Areata Treatment Alopecia areata (AA), a chronic autoimmune condition that results in unpredictable hair loss, is increasingly being managed with innovative therapies. Recent advancements signal a new era for treatment, offering hope to the estimated 7 million Americans afflicted by this condition. Understanding Alopecia Areata AA is characterized by sudden hair loss, and though it is often perceived as a cosmetic concern, its psychological impact is significant. Many individuals experience anxiety, depression, and social withdrawal as they cope with sudden baldness, particularly during formative years in childhood and adolescence. Studies have shown that those suffering from AA often face higher rates of various comorbidities, complicating their overall health. Recent Innovations: JAK Inhibitors Leading the Charge The recent approval of several Janus kinase (JAK) inhibitors, including baricitinib and ritlecitinib, has transformed the treatment landscape for patients with severe AA. Baricitinib, known commercially as Olumiant, was the first FDA-approved treatment for this condition in June 2022. Following this, ritlecitinib, marketed under the name Litfulo, received approval in 2023, offering therapy specifically suitable for adolescents ages 12 and older, marking a significant breakthrough in addressing hair loss in younger patients. Clinical Trials and Efficacy Recent clinical trials for baricitinib showcased its efficacy, with a notable percentage of participants achieving a substantial improvement in hair regrowth after 36 weeks of treatment. Similarly, ritlecitinib demonstrated significant results in early studies, with patients reporting marked decreases in scalp hair loss. The JAK inhibitors are proving to effectively modulate the immune response responsible for hair loss, restoring growth with low absolute rates of adverse events observed in trials. The Future of Alopecia Areata Treatment As the medical community continues to explore and develop treatments for AA, there remains an emphasis on understanding the pathology of the disease to ensure every patient can achieve optimal results. Given the diverse responses to JAK inhibitors, future research aims to uncover additional therapeutic avenues to benefit all individuals suffering from AA. Conclusion: Taking Action The advancements in alopecia areata treatment not only signify hope but also underline the importance of addressing the psychological and social difficulties experienced by patients. With new therapies on the horizon, individuals affected by this condition can anticipate a future where treatment efficacy and accessibility are significantly enhanced. If you or someone you know is affected by alopecia areata, consult a healthcare provider to explore available treatment options that could lead to recovery. The journey toward normalcy and confidence is within reach for those grappling with AA, and timely access to treatment can make all the difference in their lives.

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*